Dec 17, 2024 7:00am EST Immunocore announces dosing of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Dec 11, 2024 7:00am EST EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
Dec 03, 2024 1:00am EST Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Nov 06, 2024 7:00am EST Immunocore reports third quarter financial results and provides a business update
Sep 14, 2024 3:00am EDT Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Aug 08, 2024 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Aug 01, 2024 7:00am EDT Immunocore to report second quarter 2024 financial results and host call on August 8, 2024